一、被提名人已经通过青岛百洋医药股份有限公司第三届董事会提名委 员会或者独立董事专门会议资格审查，提名人与被提名人不存在利害关系 或者其他可能影响独立履职情形的密切关系。 是 □ 否 如否，请详细说明： 二、被提名人不存在《中华人民共和国公司法》第一百七十八条等规 定不得担任公司董事的情形。 是 □ 否 如否，请详细说明： 三、被提名人符合中国证监会《上市公司独立董事管理办法》和深圳 证券交易所业务规则规定的独立董事任职资格和条件。 青岛百洋医药股份有限公司 独立董事提名人声明与承诺 提名人青岛百洋医药股份有限公司董事会现就提名陆银娣为青岛百洋医药 股份有限公司第四届董事会独立董事候选人发表公开声明。被提名人已书 面同意作为青岛百洋医药股份有限公司第四届董事会独立董事候选人（参见 该独立董事候选人声明）。本次提名是在充分了解被提名人职业、学历、职 称、详细的工作经历、全部兼职、有无重大失信等不良记录等情况后作出 的，本提名人认为被提名人符合相关法律、行政法规、部门规章、规范性文 件和深圳证券交易所业务规则对独立董事候选人任职资格及独立性的要求， 具体声明并承诺如下事项： 是 □ 否 如否，请详细说明： 四、被 ...

青岛百洋医药股份有限公司 独立董事提名人声明与承诺 提名人青岛百洋医药股份有限公司董事会现就提名郝先经为青岛百洋医药 股份有限公司第四届董事会独立董事候选人发表公开声明。被提名人已书 面同意作为青岛百洋医药股份有限公司第四届董事会独立董事候选人（参见 该独立董事候选人声明）。本次提名是在充分了解被提名人职业、学历、职 称、详细的工作经历、全部兼职、有无重大失信等不良记录等情况后作出 的，本提名人认为被提名人符合相关法律、行政法规、部门规章、规范性文 件和深圳证券交易所业务规则对独立董事候选人任职资格及独立性的要求， 具体声明并承诺如下事项： 一、被提名人已经通过青岛百洋医药股份有限公司第三届董事会提名委 员会或者独立董事专门会议资格审查，提名人与被提名人不存在利害关系 或者其他可能影响独立履职情形的密切关系。 是 □ 否 如否，请详细说明： 二、被提名人不存在《中华人民共和国公司法》第一百七十八条等规 定不得担任公司董事的情形。 是 □ 否 如否，请详细说明： 三、被提名人符合中国证监会《上市公司独立董事管理办法》和深圳 证券交易所业务规则规定的独立董事任职资格和条件。 六、被提名人担任独立董事不会违反《中华 ...

| 证券代码：301015 | 证券简称：百洋医药 | 公告编号：2025-077 | | --- | --- | --- | | 债券代码：123194 | 债券简称：百洋转债 | | 青岛百洋医药股份有限公司 关于召开 2025 年第三次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1. 股东大会届次：2025年第三次临时股东大会 2. 股东大会的召集人：董事会。2025年8月27日召开的青岛百洋医药股份有 限公司（以下简称"公司"）第三届董事会第三十三次会议审议通过了《关于召 开2025年第三次临时股东大会的议案》。 3. 会议召开的合法、合规性：本次股东大会的召开符合有关法律、行政法 规、部门规章、规范性文件、深圳证券交易所业务规则和《公司章程》等的规定。 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为： 2025年9月17日9:15—9:25、9:30—11:30和13:00—15:00；通过深圳证券交易所互 联网投票系统投票的时间为：2025年9月17日9:15—15:00。 5.会 ...

| 证券代码：301015 | 证券简称：百洋医药 | 公告编号：2025-071 | | --- | --- | --- | | 债券代码：123194 | 债券简称：百洋转债 | | 青岛百洋医药股份有限公司 第三届监事会第二十七次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 青岛百洋医药股份有限公司（以下简称"公司"）第三届监事会第二十七次 会议于 2025 年 8 月 27 日以现场结合通讯的方式召开，会议通知已于 2025 年 8 月 15 日以邮件形式送达全体监事。本次会议由公司监事会主席牟君女士召集并 主持，应出席监事 3 人，实际出席监事 3 人，公司董事会秘书列席会议。本次会 议的召开符合有关法律、行政法规、部门规章、规范性文件和《公司章程》的规 定，会议决议合法、有效。 二、监事会会议审议情况 （一）审议通过了《关于<2025 年半年度报告>及其摘要的议案》； （二）审议通过了《关于 2025 年半年度募集资金存放、管理与使用情况的 专项报告的议案》； 监事会认为：公司 2025 年半年度募集资金的存 ...

| 证券代码：301015 | 证券简称：百洋医药 | 公告编号：2025-070 | | --- | --- | --- | | 债券代码：123194 | 债券简称：百洋转债 | | 青岛百洋医药股份有限公司 第三届董事会第三十三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 董事会认为：公司 2025 年半年度募集资金的存放、管理与使用情况符合中 国证监会、深圳证券交易所关于上市公司募集资金存放、管理和使用的相关规定， 符合公司《募集资金管理制度》的有关规定。 具体内容详见公司同日在巨潮资讯网（www.cninfo.com.cn）披露的《青岛百 洋医药股份有限公司关于 2025 年半年度募集资金存放、管理与使用情况的专项 报告》。 青岛百洋医药股份有限公司（以下简称"公司"）第三届董事会第三十三次 会议于 2025 年 8 月 27 日以现场结合通讯的方式召开，会议通知已于 2025 年 8 月 15 日以邮件形式送达全体董事。本次会议由公司董事长付钢先生召集并主持， 应出席董事 9 人，实际出席董事 9 人，公司 ...

东兴证券股份有限公司 关于青岛百洋医药股份有限公司 2025 年半年度持续督导跟踪报告 | 保荐机构名称：东兴证券股份有限公司 | 被保荐公司简称：百洋医药 | | --- | --- | | 保荐代表人姓名：张羽中 | 联系电话：010-66555013 | | 保荐代表人姓名：周磊 | 联系电话：010-66555013 | 一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 无 | | 2.督导公司建立健全并有效执行规章制度的情况 | | | （1）是否督导公司建立健全规章制度（包括但不限于防止 | | | 关联方占用公司资源的制度、募集资金管理制度、内控制 | 是 | | 度、内部审计制度、关联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3.募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 每月 次 1 | | （2）公司募集资金项目进展是否与信息披露文件一致 | 是 | | 4.公司治理督导情况 ...

[Important Notice, Table of Contents, and Definitions](index=2&type=section&id=Part%20I%20Important%20Notice,%20Table%20of%20Contents,%20and%20Definitions) [Important Notice](index=2&type=section&id=Important%20Notice) The board and management guarantee report accuracy, noting risks from brand concentration, drug quality, policy, and market competition, with no semi-annual dividend or capital reserve conversion plans - The company's board of directors, supervisory board, and senior management guarantee the report's truthfulness, accuracy, and completeness[4](index=4&type=chunk) - The company faces risks from concentrated brand operations, drug quality, policy changes, and intensified market competition[4](index=4&type=chunk) - The company plans no semi-annual cash dividends, bonus shares, or capital reserve conversions[5](index=5&type=chunk) [Table of Contents](index=3&type=section&id=Table%20of%20Contents) The report is clearly structured into eight main chapters, facilitating comprehensive investor understanding of the company - The report is clearly structured into eight main chapters, facilitating comprehensive investor understanding of the company[7](index=7&type=chunk) [List of Documents for Reference](index=4&type=section&id=List%20of%20Documents%20for%20Reference) Documents for reference include signed financial statements, publicly disclosed originals, and other relevant files, all available at the company's securities department - Documents for reference include signed financial statements, publicly disclosed originals, and announcement drafts[9](index=9&type=chunk) - All documents for reference are kept at the company's securities department[10](index=10&type=chunk) [Definitions](index=5&type=section&id=Definitions) This section defines key entities, regulatory bodies, reporting period, and pharmaceutical terms (e.g., OTC, DTP, B2C) for accurate report understanding - Key entities like the company, controlling shareholder, and subsidiaries are clearly defined[11](index=11&type=chunk) - Key pharmaceutical terms (e.g., prescription drugs, OTX, OTC, 'Two-Invoice System', DTP, B2C) are explained for accurate report understanding[11](index=11&type=chunk) - The reporting period is January-June 2025; the prior year period is January-June 2024[11](index=11&type=chunk) [Company Profile and Key Financial Indicators](index=6&type=section&id=Part%20II%20Company%20Profile%20and%20Key%20Financial%20Indicators) [Company Profile](index=6&type=section&id=Company%20Profile) Qingdao Baiyang Pharmaceutical Co., Ltd. is listed on Shenzhen Stock Exchange (301015), with Fu Gang as legal representative Company Basic Information | Indicator | Content | | :--- | :--- | | Stock Abbreviation | Baiyang Pharmaceutical | | Stock Code | 301015 | | Listing Exchange | Shenzhen Stock Exchange | | Chinese Name | Qingdao Baiyang Pharmaceutical Co., Ltd. | | Legal Representative | Fu Gang | [Contact Person and Information](index=6&type=section&id=Contact%20Person%20and%20Information) Board Secretary Li Zhen and Securities Rep Liu Nina share contact info: Building 1, No. 88 Tongbai Road, Qingdao, Phone 0532-66756688, Email byyy@baheal.com Contact Information | Position | Name | Contact Address | Phone | Email | | :--- | :--- | :--- | :--- | :--- | | Board Secretary | Li Zhen | Building 1, No. 88 Tongbai Road, Shibei District, Qingdao City, Shandong Province | 0532-66756688 | byyy@baheal.com | | Securities Affairs Representative | Liu Nina | Building 1, No. 88 Tongbai Road, Shibei District, Qingdao City, Shandong Province | 0532-66756688 | byyy@baheal.com | [Other Information](index=6&type=section&id=Other%20Information) Company's registered address, office address, website, email, disclosure locations, and registration status remained unchanged - Company contact, disclosure, and registration details remained unchanged during the reporting period[15](index=15&type=chunk)[16](index=16&type=chunk)[17](index=17&type=chunk) [Key Accounting Data and Financial Indicators](index=7&type=section&id=Key%20Accounting%20Data%20and%20Financial%20Indicators) In H1 2025, revenue decreased 6.02% to **3.751 billion yuan**, net profit fell 59.48% to **163 million yuan**, EPS was **0.31 yuan/share** (down 59.74%), total assets rose 0.67%, and net assets decreased 8.63% Key Accounting Data and Financial Indicators (Year-on-year) | Indicator | Current Reporting Period (million yuan) | Prior Year Period (million yuan) | Year-on-year Change | | :--- | :--- | :--- | :--- | | Operating Revenue | 3,751.29 | 3,991.56 | -6.02% | | Net Profit Attributable to Shareholders of Listed Company | 163.14 | 402.63 | -59.48% | | Net Profit Attributable to Shareholders of Listed Company After Deducting Non-recurring Gains and Losses | 177.37 | 370.76 | -52.16% | | Net Cash Flow from Operating Activities | 391.76 | 471.62 | -16.93% | | Basic Earnings Per Share (yuan/share) | 0.31 | 0.77 | -59.74% | | Diluted Earnings Per Share (yuan/share) | 0.31 | 0.74 | -58.11% | | Weighted Average Return on Net Assets | 7.07% | 13.51% | -6.44% | Asset and Liability Indicators (Period-end) | Indicator | End of Current Reporting Period (million yuan) | End of Prior Year (million yuan) | Change | | :--- | :--- | :--- | :--- | | Total Assets | 7,159.89 | 7,112.58 | 0.67% | | Net Assets Attributable to Shareholders of Listed Company | 2,169.93 | 2,374.91 | -8.63% | [Differences in Accounting Data under Domestic and Overseas Accounting Standards](index=7&type=section&id=Differences%20in%20Accounting%20Data%20under%20Domestic%20and%20Overseas%20Accounting%20Standards) No accounting data differences existed under domestic and overseas accounting standards during the reporting period - No accounting data differences existed under domestic and overseas accounting standards during the reporting period[19](index=19&type=chunk)[20](index=20&type=chunk) [Non-recurring Gains and Losses and Amounts](index=7&type=section&id=Non-recurring%20Gains%20and%20Losses%20and%20Amounts) Total non-recurring gains and losses were **-14.24 million yuan**, mainly from asset disposal, government grants, financial asset fair value changes, capital occupation fees, and non-operating items Non-recurring Gains and Losses and Amounts | Item | Amount (million yuan) | Description | | :--- | :--- | :--- | | Gains/Losses from Disposal of Non-current Assets | 0.62 | | | Government Grants Recognized in Current Profit or Loss | 19.33 | Primarily investment attraction rewards, special funds for social and economic development, and high-quality development policy funds for the biomedical industry | | Gains/Losses from Fair Value Changes and Disposal of Financial Assets and Liabilities Held by Non-financial Enterprises, Excluding Effective Hedging Activities Related to the Company's Normal Operations | -25.27 | Primarily fair value changes in Zhongkang Holdings and Huahao Zhongtian Pharmaceutical shares | | Capital Occupation Fees Received from Non-financial Enterprises Recognized in Current Profit or Loss | 1.12 | | | Other Non-operating Income and Expenses Apart from the Above Items | -5.73 | Primarily donation expenses | | Other Profit and Loss Items Meeting the Definition of Non-recurring Gains and Losses | 0.44 | | | Less: Income Tax Impact | -1.81 | | | Impact on Minority Interests (After Tax) | 6.57 | | | Total | -14.24 | | - The company does not classify non-recurring gains and losses as recurring gains and losses[24](index=24&type=chunk) [Management Discussion and Analysis](index=9&type=section&id=Part%20III%20Management%20Discussion%20and%20Analysis) [Main Business Activities During the Reporting Period](index=9&type=section&id=Main%20Business%20Activities%20During%20the%20Reporting%20Period) As an innovative brand commercialization platform, the company focuses on product development, manufacturing, and commercialization of medical innovations, steadily transforming into an innovative pharmaceutical enterprise, with stable brand operations, reduced wholesale, and stable retail business, actively deploying innovative products in oncology and bone health [Industry Overview](index=9&type=section&id=%EF%BC%88%E4%B8%80%EF%BC%89%E5%85%AC%E5%8F%B8%E6%89%80%E5%B1%9E%E8%A1%8C%E4%B8%9A%E6%83%85%E5%86%B5) In H1 2025, China's pharmaceutical industry developed steadily under deepening policies, technological innovation, and capital empowerment, with market size expected to exceed **3.5 trillion yuan** - In H1 2025, NMPA approved 43 innovative drugs, a **59%** year-on-year increase[26](index=26&type=chunk) - China's pharmaceutical market size is expected to exceed **3.5 trillion yuan** in 2025[27](index=27&type=chunk) - The industry is accelerating its transformation from 'imitation' to 'leading' and 'original innovation'[27](index=27&type=chunk) [Company's Strategic Innovation and Upgrading](index=9&type=section&id=%EF%BC%88%E4%BA%8C%EF%BC%89%E5%85%

百洋医药公告，2025年上半年营业收入37.51亿元，同比下降6.02%。净利润1.63亿元，同比下降 59.48%。公司计划不派发现金红利，不送红股，不以公积金转增股本。 ...

Market Overview - The pharmaceutical commercial sector experienced a decline of 2.71% on August 27, with Saily Medical leading the drop [1] - The Shanghai Composite Index closed at 3800.35, down 1.76%, while the Shenzhen Component Index closed at 12295.07, down 1.43% [1] Individual Stock Performance - Saily Medical (603716) closed at 33.15, down 8.93% with a trading volume of 484,700 shares and a transaction value of 1.671 billion [1] - Other notable declines included HeLiang China (603122) down 5.15%, YaoYigou (300937) down 5.10%, and Guofa Shares (600538) down 4.98% [1] - The overall net outflow of main funds from the pharmaceutical commercial sector was 543 million, while retail investors saw a net inflow of 361 million [1] Fund Flow Analysis - Jiuzhoutong (600998) had a main fund net inflow of 11.8 million, accounting for 18.23% of its total [2] - Dacilin (603233) saw a main fund net inflow of 29.97 million, representing 15.70% [2] - The overall trend indicates a mixed sentiment with main funds withdrawing while retail investors are actively buying [2]

Market Overview - The pharmaceutical commercial sector rose by 0.12% on August 26, with Saily Medical leading the gains [1] - The Shanghai Composite Index closed at 3868.38, down by 0.39%, while the Shenzhen Component Index closed at 12473.17, up by 0.26% [1] Stock Performance - Saily Medical (603716) closed at 36.40, up by 4.99% with a trading volume of 707,500 shares and a transaction value of 2.592 billion [1] - Baiyang Pharmaceutical (301015) closed at 25.78, up by 2.14% with a trading volume of 96,000 shares and a transaction value of 247 million [1] - Other notable performers include: - People's Tongtai (600829) at 8.47, up by 1.68% [1] - Luyuan Pharmaceutical (002788) at 8.85, up by 0.91% [1] - Yiyigou (300937) at 30.17, up by 0.90% [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 502 million from institutional investors, while retail investors saw a net inflow of 453 million [2] - The overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors increased their positions [2] Individual Stock Capital Flow - People's Tongtai (600829) had a net inflow of 24.93 million from institutional investors, but a net outflow of 28.53 million from retail investors [3] - Baiyang Pharmaceutical (301015) saw a net inflow of 16.19 million from institutional investors, with retail investors withdrawing 14.69 million [3] - Other stocks with significant capital movements include: - Swiss Pharmaceutical (002589) with a net inflow of 14.79 million from institutional investors [3] - National Pharmaceutical (600511) with a net inflow of 11.70 million from institutional investors [3]